Alnylam Pharmaceuticals
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Below its 200-day average and near the bottom of the universe on momentum.
- Signal has read STRONG SELL for 4 months.
- Its last 6 Sell calls were actually followed by a +3% average gain three months out - this one has bounced back faster than the signal expected.
- Recent price momentum is -52.5% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has risen to 4.1% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is below the 60-day average, a short-term downtrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2848 U.S. stocks StockVane covers.
Last computed: 2026-11-22 02:27 UTC
Data coverage: 5 of 6 factors. Missing data is not a zero score.
The radar needs all six factors. Available grades are shown below.
Valuation C+
How expensive the stock is versus earnings, sales and its own 5-year history.
| P/E (TTM) | 7.5x | Better than 91% |
| Forward P/E | 20.2x | Better than 36% |
| Price / Sales | 3.8x | Better than 31% |
| P/E vs own 5-yr range | 79th pctl | Better than 27% |
Growth N/A
How fast revenue, profit and free cash flow are compounding.
Not enough data to grade this factor.
Profitability A
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 81.6% | Better than 91% |
| Operating margin | 13.5% | Better than 61% |
| Net margin | 8.4% | Better than 55% |
| Return on equity | 73.3% | Better than 96% |
| Return on invested capital | 26.3% | Better than 94% |
Momentum D-
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -39.1% | Better than 11% |
| 6-month return | -51.6% | Better than 7% |
| 12-month return (ex latest month) | -48.7% | Better than 3% |
| Distance below 52-week high | 70.0% | Better than 6% |
Financial Health B
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 2.8x | Better than 70% |
| Debt to assets | 25.7% | Better than 48% |
| Interest coverage | 2.3x | Better than 39% |
| Free cash flow / net income | 148.3% | Better than 65% |
Analyst View A-
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 76.0% | Better than 56% |
| Upside to average target | 106.9% | Better than 85% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 147.82
- Open
- 148.35
- Day range
- 143.40 - 151.41
- Avg price
- 146.44
- Volume
- 2.33M
- Turnover
- 340.96M
- Turnover ratei
- 1.74%
- Volume ratioi
- 0.93
- Amplitudei
- 5.42%
- 52-week rangei
- 143.40 - 479.79
Valuation
- P/Ei
- 61.73
- P/E (TTM)i
- 7.48
- P/Bi
- 5.35
- EPSi
- 2.33
- Book value / shi
- 26.91
- Net profit
- 312.07M
- Net assets
- 3.60B
Share structure
- Market cap
- 19.26B
- Float capi
- 19.22B
- Shares out
- 133.94M
- Float sharesi
- 133.64M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 1970-01-01
70.0% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-201.87M net over the window
Short interest
- Shares short
- 5.47M
- % of floati
- 4.08%
- Days to coveri
- 1.91
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Alnylam Pharmaceuticals (ALNY)?
Alnylam Pharmaceuticals last traded at 143.82. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Alnylam Pharmaceuticals's market cap?
About 19.26B.
What is the P/E ratio of Alnylam Pharmaceuticals?
The trailing twelve-month P/E is 7.48, below its own 5-year average of 19.64 — toward the top of its historical range (78.79% percentile). See the Valuation tab for the full history.
Does Alnylam Pharmaceuticals pay a dividend?
Alnylam Pharmaceuticals does not currently pay a regular dividend.
Is Alnylam Pharmaceuticals a buy according to analysts?
The consensus of 25 analysts is a Buy rating, with an average 12-month price target of 297.59, which implies 106.9% upside from the current price. This is not investment advice.
What is Alnylam Pharmaceuticals's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Alnylam Pharmaceuticals a E (Strong Sell). Below its 200-day average and near the bottom of the universe on momentum. Not investment advice.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Alnylam Pharmaceuticals discussion 0 comments